Navigation Links
Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
Date:4/22/2008

gin the delivery in fall 2008 of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. Other HGS drugs in clinical development include two TRAIL receptor antibodies for the treatment of cancer. In addition, HGS1029, a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins, is expected to enter Phase 1 clinical trials for the treatment of cancer in early 2008. HGS also has substantial financial rights to certain products in the GlaxoSmithKline clinical development pipeline.

For information about HGS, please visit the Company's web site at http://www.hgsi.com . Health professionals or patients interested in clinical trials of HGS products may inquire via email to clinical_trials@hgsi.com, or by calling (301) 610-5790, extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the un
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
2. Data Show SuperGens MP-470 is Safe in Humans
3. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
4. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
5. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
6. ExonHits EHT 0202 Counters Scopolamines Detrimental Effects on Cognition in Humans
7. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm
8. Synbiotics Corporation Announces Human Submission for FluDetect(R)
9. GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
10. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
11. N30 Pharma Announces Successful Initiation of Human Studies With N30-201
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 AFFiRiS AG ... York results of AFF008, a Phase I clinical ... the first therapy against the protein alpha-synuclein, a promising Parkinson,s ... J. Fox Foundation for Parkinson,s Research (MJFF) supported the study ... press conference on the impact a disease-modifying therapy would have ...
(Date:7/31/2014)... , July 31, 2014 genae, a ... industries, announced today the incorporation of genae UK in ... has one of the largest medical device markets in the ... it is projected to increase by a CAGR of 6.0% until ... equal to 9.5% of GDP. Despite recessionary pressures, market growth rates ...
(Date:7/31/2014)... AUSTIN, Texas , July 31, 2014 Vermillion, ... cancers and women,s health, will hold a conference call on ... discuss results for the second quarter ended June 30, 2014. ... to the call. Vermillion,s Chairman, President and CEO ... a question and answer period. Date: Thursday, August ...
Breaking Medicine Technology:First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4genae Opens Offices in London 2Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
... has collaborated with the National Comprehensive Cancer Network® (NCCN®) ... ( NCCN Guidelines ™) into Elekta,s MOSAIQ® Oncology Information ... NCCN,s evidence-based clinical content directly from within the MOSAIQ ... Guidelines are widely recognized as the standard ...
... 8, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Product Development of BioMarin, will present a company update at ... June 15, 2011 at 10:00 a.m. CT.   ... conference call via the investor section of the BioMarin website, ...
Cached Medicine Technology:National Comprehensive Cancer Network Guidelines Available in Elekta's MOSAIQ EMR 2BioMarin to Present at the William Blair Growth Stock Conference 2
(Date:7/31/2014)... NY (PRWEB) July 31, 2014 NEWwoodworks, ... , is expanding their brand presence with a website ... over 20 years, NEWwoodworks has specialized in handcrafted cabinetry, ... interior furnishings. NEWwoodworks has earned a reputation for taking ... dare take on. They commonly craft with reclaimed wood, ...
(Date:7/31/2014)... Ticket Down is a dependable source for authentic ... Sun Life Stadium in Miami on Monday, August 4th. ... and diehard soccer fans from the Miami, Florida area are ... Cup final in person at Sun Life Stadium. ... split into two groups where they will then play each ...
(Date:7/31/2014)... 2014 The VitaSleep FDA cleared ... and provide an easier breathing capacity by slightly adjusting ... that people can breathe easier and helps reduce or ... so that it can meet the needs of each ... often shared by actual customer reviews. Johathan R. ...
(Date:7/31/2014)... Denver, Colorado (PRWEB) July 31, 2014 ... commonly doctors recommend pain killers for this health problem. ... reveals that this new program was created by Peter ... purpose to help sufferers from all over the world ... , If people wish to view pros and ...
(Date:7/31/2014)... 31, 2014 A program for anyone ... to the University of Colorado Anschutz Health and ... loss boot camp and transformation program. , “Extreme ... and Eyeworks USA, is an evidenced-based program inspired by ... by Eyeworks USA. This season, the show has participants ...
Breaking Medicine News(10 mins):Health News:NEWwoodworks Fine Woodworking Group Launches New Website 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 3Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 2Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 3Health News:New Dental Device Reviews to Stop Snoring by VitalSleep 2Health News:Neuropathy Miracle Review Reveals Peter Bansby's Unique Cure Method 2Health News:"Extreme Weight Loss: Destination Boot Camp" Comes to Colorado - The CU Anschutz Health and Wellness Center Begins Transformational Program 2Health News:"Extreme Weight Loss: Destination Boot Camp" Comes to Colorado - The CU Anschutz Health and Wellness Center Begins Transformational Program 3
... Blue branded dental plan,to central Pennsylvania (Lehigh Valley) ... BlueCross announced,today that it is acquiring Dominion Dental ... The move by the region,s,leading health insurer adds ... the Mid-Atlantic Region., "Helping to improve the ...
... Nov. 4 Hospira, Inc.,(NYSE: HSP ), ... announced that Christopher B. Begley, chairman and chief,executive ... Finance,and chief financial officer, will make a formal ... Conference on Wednesday, Nov. 12, 2008, in,Phoenix., ...
... PH ), the global leader in motion ... the purchase of Matrx nitrous oxide,delivery systems from ... to expand its geographic market space for dental ... American base of operations. The,product line will be ...
... Nov. 4 Allied Minds funds research to ... dermal fillers.,Allied Minds, a seed investment firm specializing ... research with Lawrence Berkeley National,Laboratory through creation of ... Eva Turley and Mina Bissell will develop a,technology ...
... of Minnesota Leverages Market Dynamics With New, Plan Offering ... ... NASHVILLE, Tenn., Nov. 4 ,HealthLeaders-InterStudy, a leading provider of managed ... the,national trend of moving from fully insured to self-insured health plans.,According ...
... Sold by A Uniquely-Trained Sales ... ... today announced that SANCUSO(R) (Granisetron Transdermal System),is now available by prescription for ... approved by,the U.S. Food and Drug Administration (F.D.A.) in September 2008 as ...
Cached Medicine News:Health News:Capital BlueCross Acquires Dominion Dental 2Health News:Parker Acquires Medical Gas Delivery Product Line, Expanding Its Dental Equipment Offering 2Health News:Parker Acquires Medical Gas Delivery Product Line, Expanding Its Dental Equipment Offering 3Health News:New Skin Rejuvenation Discovery Receives Commercial Backing 2Health News:Minnesota Employers Buck National Trend and Largely Remain Fully-Insured 2Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 2Health News:SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Chemotherapy Patients, Now Available 3
Retractable, straight double Lancet Blade, 15 Degree Angle , available in variations; Titanium handle...
10mm Tip to Bend, 0.3mm Y Tip; In Titanium....
Bend with "H" Shaped Tip, LEFT; in Titanium....
Bend with "H" Shaped Tip, Right; Stainless Steel....
Medicine Products: